Cholera toxin B subunit is known for its adjuvant properties when associated with different antigens. In this work, we have fused the ctxB gene to the pneumococcal surface protein (pspA) gene from Streptococcus pneumoniae. Intradermal administration of the fusion protein in mice induced anti-PspA antibodies and protection against pneumococcus in a sepsis model.
Cholera toxin B subunit is known for its adjuvant properties when associated with different antigens. In this work, we have fused the ctxB gene to the pneumococcal surface protein (pspA) gene from Streptococcus pneumoniae. Intradermal administration of the fusion protein in mice induced anti-PspA antibodies and protection against pneumococcus in a sepsis model.
Streptococcus pneumoniae is the major cause of bacterial pneumonia, meningitis, and otitis media cases around the world, leading to up to 1 million deaths per year. Pneumococcal surface protein A (PspA) is a virulence factor partially conserved among the Streptococcus pneumoniae isolates that plays a role in complement inactivation during infection (18) . Based on amino acid sequence diversity, PspAs can be classified into three families and six clades (8) that also display immunological cross-reactivity among themselves (17) . In several pneumoccocal infection challenge models, PspA has proved to be a good vaccine candidate when administered either in protein-adjuvant formulations or in DNA-based vaccines (4, 11, 12) . PspA was also shown to bind and to prevent the bactericidal activity of apolactoferrin (15) , present in saliva and other mucosal secretions. In addition, anti-PspA antibodies were shown to enhance pneumococcal killing by lactoferrin, suggesting a mechanism for the reduction of pneumococcal carriage by these antibodies (15) . In a recent work, we tested the immunogenic potential of a fusion protein composed of the cholera toxin B subunit (CTB) and pneumococcal surface antigen A from Streptococcus pneumoniae by intranasal inoculation of mice (3) . In this work, we have amplified the 5Ј terminus region (which encodes the ␣-helix region plus the prolinerich domain) of the pspA clade 3 gene from pTG-pspAЈ3 (11) (pspAЈ3 accession number, AY082389), which carried the gene isolated from S. pneumoniae St 259/98 strain (Instituto Adolpho Lutz, São Paulo, SP, Brazil). The pspAЈ gene was then cloned downstream of the ctxB gene in the pAE-CTB plasmid (2) in order to express a CTB-PspAЈ fusion protein in Escherichia coli. Using this expression system, the recombinant protein contains an N-terminal six-His tag that allows purification through Ni 2ϩ charged columns. This system was used for the expression and purification of the fusion protein CTB-PspAЈ and CTB, as previously described (2, 3) , and PspAЈ, with the observation that the last protein did not adsorb very well, and it was released from the column with 20 mmol · liter Ϫ1 imidazole.
Protein characterization. The recombinant CTB-PspAЈ purified from E. coli BL21-SI extracts was able to form pentamers, as evaluated by 6% sodium dodecyl sulfate-polyacrylamide gel electrophoresis of unboiled samples (data not shown). Since the adjuvant effect of CTB is dependent on the binding of the pentameric form to the GM1 gangliosides present on cellular surfaces (14), we performed an enzyme-linked immunosorbent assay (ELISA) experiment, using 10 g · ml Ϫ1 GM1 in phosphate-buffered saline for an overnight coating and increasing amounts of CTB-PspAЈ, as previously described (3). Briefly, after an incubation of 1 h with the proteins, anti-CTB antiserum was added at the proper dilution, followed by a 1-h incubation at 37°C, and the reaction was developed using antimouse immunoglobulin G (IgG)-peroxidase conjugate. The results show that CTB-PspAЈ was able to bind to GM1 to the same extent as CTB alone and in a dose-dependent manner ( Fig. 1 ). Recombinant PspAЈ, also expressed and purified from E. coli extracts using the same expression vector and Ni 2ϩ affinity chromatography, was not able to bind to GM1 even in the highest concentration used. None of the proteins were able to bind when 10 g · ml Ϫ1 bovine serum albumin was used as a coating (Fig. 1) .
Immunization of mice. To test the immunogenic potential of CTB-PspAЈ, 6-week-old female BALB/c mice from Instituto Butantan, São Paulo, Brazil, received by the intradermal route either the CTB-PspAЈ protein (5.6 g) or the controls-saline, CTB (1.6 g), PspAЈ (4.0 g), and PspAЈ (4.0 g) coadministered with CTB (1.6 g)-twice a week for three consecutive weeks. The total volume administered to each animal was 100 l. One group received one dose of the commercial Pneumovax vaccine (Merck Sharp Dohme) intraperitoneally (i.p.) 2 weeks before the challenge as a positive control. Another group received 5.6 g of CTB-PspAЈ, diluted in 10 l of saline, by the intranasal route. The mass of CTB and PspAЈ used in this experiment was determined according to the molar concentrations of the two proteins present in 5.6 g of the fusion protein. Three weeks after the last immunization, the mice were bled through the retroorbital plexus. Anti-PspAЈ antibod-ies were measured in the sera by ELISA, using recombinant PspAЈ as a coating. The titer was defined as the dilution that gave an absorbance of 0.1 at 492 nm. The results were compared using Student's t test.
As observed in Fig. 2 , the highest titers of anti-PspAЈ IgG were achieved in the animals that received the combination of CTB and PspAЈ or the fusion protein CTB-PspAЈ. The levels of anti-PspA IgG from these groups were significantly different from those of the groups that received saline (P Ͻ 0.001), CTB (P Ͻ 0.001), or PspAЈ alone (P Ͻ 0.05). The levels of anti-PspA IgG for the group that received CTB-PspA by the intranasal route were not significantly different from that of the saline group. As expected, Pneumovax, which is a polysaccharidebased vaccine, did not induce significant amounts of antiPspAЈ IgG.
Intraperitoneal challenge. After analysis of anti-PspAЈ IgG in the sera, the animals underwent an intraperitoneal challenge with Table 1 . Partial protection was observed in mice immunized intradermally with commercial Pneumovax vaccine (65%) or the CTB-PspAЈ fusion protein (56%). These values were significantly different from those for the groups that received either saline or CTB (P Ͻ 0.05 by the Fisher exact test). When the CTB-PspAЈ was administered by the intranasal route, no increase in survival was observed. Intradermal immunization with a mixture of PspAЈ and CTB elicited very high levels of IgG antibody to PspA (Fig. 2 ) but did not elicit protection (Table 1 ). In addition, no correlations between antiPspAЈ IgG levels and survival or median survival time were observed when the animals were analyzed individually. In the search for protein candidates for the development of a vaccine against S. pneumoniae with good efficacy in children and elderly and immunocompromised individuals, PspA antigen has been extensively studied in recent years. Antibodies to PspA have proved to be protective in different pneumococcal challenge models developed in animals (19) , even when used as therapy a few hours after infection (16) . Moreover, PspA Ϫ pneumococcus strains are less pathogenic than their wild-type counterparts (5) . The basis for the protection exerted by antiPspA antibodies has been addressed in different works and appears to be related to a decrease in the inhibition of complement deposition caused by PspA (13) during infection and an enhancement in pneumococcal killing by apolactoferrin present in mucosal secretions (15) . In this work, we investigated the potential of a CTB-PspAЈ fusion protein to induce protective anti-PspA antibodies upon intradermal immunization. The intradermal route was chosen based on our preliminary results showing that the intranasal route was less efficient for the induction of anti-PspAЈ IgG in the sera (data not shown). The lower antibody levels could be a problem, since protection in a sepsis model is attributed to the presence of IgG in the serum, which is corroborated by the efficiency of passive immunization at protecting mice from fatal infection with S. pneumoniae (6, 16) . CTB has proved to be a good adjuvant for different antigens when administered through the mucosa (9, 10) . More recently, some groups have published the adjuvant effect of CTB when inoculated through the skin, such as the transcutaneous or epidermal route (1, 7) , by a Th1-predominant mechanism. Our results have shown that intradermal immunization with CTB-PspAЈ protein partially protected mice against an intraperitoneal challenge with an S. pneumoniae strain that expressed a homologous PspA. The protection was similar to that observed for the Pneumovax vaccine in our experiments but was significantly different from that observed for the group that received PspAЈ in combination with CTB. Interestingly, the levels of anti-PspAЈ IgG elicited by the group that received CTB-PspAЈ or a combination of the two proteins were about the same. Given the fact that the animals with the highest antibody titers were not necessarily protected, other mechanisms seem to be involved. So far, the only factor that we have been able to associate with this result is the lower IgG1/IgG2a ratio (r) displayed by immunization with CTB-PspAЈ (r ϭ 4) compared to that induced by PspAЈ alone (r ϭ 32) or by PspAЈ plus CTB (r ϭ 16). It is thought that a balanced immune response, in terms of IgG1 and IgG2a production, is suitable for protection against a lethal challenge with a virulent strain of S. pneumoniae (11) . In addition to the immunological efficacy of this fusion protein, the manufacturing process appears to be easier and less expensive, since a single fermentation step is required for the production of the adjuvant and the antigen desired. Also, the functionality of the final recombinant product can be easily assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, in which the samples do not undergo heat treatment, and by a GM1 ELISA. The partial protection against S. pneumoniae intraperitoneal challenge indicates that CTB-PspAЈ may be considered a promising vaccine component. 
